Evidence map›Paper›PMID 35587859›Full record

ReviewCurrent pain and headache reports2022

Drug Safety in Episodic Migraine Management in Adults. Part 2: Preventive Treatments.

Abigail L Chua, Sandhya Mehla, Yulia Y Orlova

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pain and headache reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Abigail L ChuaGeisinger Health Systems, Neurology, 1000 E. Mountain Boulevard, Wilkes-Barre, PA, 18711, USA. achua@geisinger.edu.ORCID http://orcid.org/0000-0002-6092-0082
Sandhya MehlaAyer Neurosciences Institute, Hartford HealthCare Medical Group, University of Connecticut School of Medicine, Norwich, CT, USA.
Yulia Y OrlovaNeurology Department, University of Florida, Gainesville, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe aim of this review is to aid in decision-making when choosing safe and effective options for preventive migraine medications. RECENT

findingsIn Part 2, we have compiled clinically relevant safety considerations for commonly used migraine prophylactic treatments. Preventive treatment of episodic migraine includes nonspecific and migraine-specific drugs. While medications from several pharmacological classes-such as anticonvulsants, beta-blockers, and antidepressants-have an established efficacy in migraine prevention, they are associated with a number of side effects. The safety of migraine-specific treatments such as anti-CGRP monoclonal antibodies and gepants are also discussed. This review highlights safety concerns of commonly used migraine prophylactic agents and offers suggestions on how to mitigate those risks.

Indexed as

Calcitonin Gene-Related PeptideMigraine DisordersAdultAntibodies, MonoclonalAnticonvulsantsCalcitonin Gene-Related Peptide Receptor AntagonistsHumansAntibodies, MonoclonalAnticonvulsantsCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsAnticonvulsantsAntidepressantsBeta-blockerCGRPMigraine preventionRisk

Identifiers

PMID35587859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.